### (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 29 July 2004 (29.07.2004)

**PCT** 

# (10) International Publication Number WO 2004/063712 A3

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68, C12P 19/34, C07H 21/02, 21/04, G01N 33/574, C07K 14/435
- (21) International Application Number:

PCT/US2004/000447

- (22) International Filing Date: 9 January 2004 (09.01.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/438,861

9 January 2003 (09.01.2003) US

- (71) Applicant (for all designated States except US): CHIL-DREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ZETTER, Bruce [US/US]; 41 Grove Street, Wayland, MA 01778 (US). HUTCHINSON, Lloyd [US/US]; 69 Fuller Street, Brookline, MA 02446 (US). BAO, Lere [CN/US]; 145 Day Street, Newton, MA 02466 (US).
- (74) Agents: RESNICK, David, S. et al.; Nixon Peabody LLP, 100 Summer Streett, Boston, MA 02110-2131 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 31 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER

(57) Abstract: We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasma (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316 has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316 in a biological test sample obtained from the patient are provided.





# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/00447

A. CLASSIFICATION OF SUBJECT MATTER					
IPC(7) : C12Q 1/68; C12P 19/34; C07H 21/02, 21/04; GO 1N 33/574; C07K 14/435					
1 US CL : 435/6, 7:1, 91.2; 536/23.1, 23.5, 24.31, 24.33; 530/350, 387 1					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum do	cumentation searched (classification system followed	by classification symbols)	<del></del>		
U.S. : 4	35/6, 7.1, 91.2; 536/23.1, 23.5, 24.31, 24.33; 530/3	350. 387.1			
İ	, , , , , , , , , , , , , , , , , , , ,	,			
Documentation	on searched other than minimum documentation to th	e extent that such documents are included in	the fields searched		
Fig. 1					
Electronic da	ta base consulted during the international search (nan	ne of data base and, where practicable, sear	ch terms used)		
Please See C	ontinuation Sheet				
ł					
C. DOCI	UMENTS CONSIDERED TO BE RELEVANT				
Category *					
	Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.		
Y	US 6,150,117 A (ZETTER et al) 21 November 200	00 (21.11.2000), columns 4-6.	1-16		
.,					
Y	SHOU et al. Expression profiling of a human cell l	ine model of prostatic cancer reveals a	1-16		
	direct involvement of interferon signaling in prostat	e tumor progression Proceedings of the			
	National Academies of Science, USA. 05 March 20	002, Vol. 99, No. 5, pages 2830-2835,			
	see especially pages 2833-2834.				
}					
Y	YOKOYAMA et al. Identification and cloning of no	euroblastoma-specific and nerve tissue-	1-16		
	specific genes through compiled expression profiles	. DNA Research. 1996, Vol. 3, No. 5.	1 10		
	pages 311-320.	, , , , ,	•		
			İ		
		İ			
		i			
		i			
Front -					
	documents are listed in the continuation of Box C.	See patent family annex.	i		
* Sp	ecial categories of cited documents:	"T" later document published after the intern	national filing date or priority		
"A" document	defining the general state of the art which is not considered to be	date and not in conflict with the applica	tion but cited to understand the		
of particula	ar relevance	principle or theory underlying the inven	tion		
#T'P 41		"X" document of particular relevance; the cl	simed invention cannot be		
"E" earlier app	lication or patent published on or after the international filing date	considered novel or cannot be considered	ed to involve an inventive step		
"L" document	which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone	•		
estabiish th	e publication date of another citation or other special reason (as	"Y" document of particular relevance; the cl	olmed leverties t		
specified)	• • • • • • • • • • • • • • • • • • • •	considered to involve an inventive step v	when the document is		
"O" document r	referring to an oral disclosure, use, exhibition or other means	combined with one or more other such of	locuments, such combination		
		being obvious to a person skilled in the	art		
"P" document p	published prior to the international filing date but later than the	"&" document member of the same patent fa	mily		
priority date claimed					
Date of the act	Date of the actual completion of the international search  Date of mailing of the international search report				
Od Tannam 200	05 (04 01 2005)	21 IAN 2005			
Name and mai	05 (04.01.2005)	DI DHM COO			
	ling address of the ISA/US	Authorized officer Mana 1/	tata		
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Authorized officer Maria I Walso  Carla Myers			
P.O.	Box 1450	77,013	İ		
Alexa	undria, Virginia 22313-1450	Telephone No. 571-272-1600			
Facsimile No. (703) 305-3230					
- DOMAGA		<u></u>			

Form PCT/ISA/210 (second sheet) (January 2004)

TATTED NATIONAL COLUMN	International application No.	
INTERNATIONAL SEARCH REPORT	PCT/US04/00447	
	•	
Continuation of B. FIELDS SEARCHED Item 3:		
WEST: US, EP, JP, WO patents: DIALOG: MEDI INF CA BIOSIS EMPASE	SCISEARCH; EMBL, GenBank, EST-database.	
search terms: SEQ ID NO: 1-3, thymosin beta-16, NB thymosin, TYBN_human, TI	MSNB	
·		
	İ	
	İ	
	·	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/00447

Box No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
mvention, in	to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed e international search was carried out on the basis of: of material a sequence listing
	table(s) related to the sequence listing
b. forma	in written format in computer readable form
c. time o	of filing/furnishing  contained in the international application as filed  filed together with the international application in computer readable form
$\boxtimes$	furnished subsequently to this Authority for the purposes of search
піеа	idition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been or furnished, the required statements that the information in the subsequent or additional copies is identical to that in application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additi	onal comments: